Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683739 | 0.86 | CYP2D6 (0.48) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL3450044 | 0.86 | CYP2D6 (0.48) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL3450045 | 0.86 | CYP2D6 (0.48) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL5861606 | 0.86 | CYP2D6 (0.48) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL7208477 | 0.85 | CHRM2 (0.34) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL7208474 | 0.85 | CHRM2 (0.34) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL9641197 | 0.83 | CHRNB2 (0.38) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL14665843 | 0.82 | CTSC (0.40) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL14598760 | 0.82 | CTSC (0.40) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL13026171 | 0.82 | CTSC (0.40) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312890-A1 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110275713-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312890-A1 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | PLTP, GP6, PDGFA | CHRM2 3988/4885CHRM4 4476/4885CHRM1 3624/4885 |
| US-20110275713-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | PLTP, GP6, PDGFA | CHRM2 3988/4885CHRM4 4476/4885CHRM1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.